MYNZ Mainz Biomed B.V. Stock Quote

MYNZ [NASD]

Healthcare | Diagnostics & Research | Germany

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	11.71M	Perf Week	-43.98%
Market Cap	182.09M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	49.66%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.02	Perf Half Y	-
Book/sh	0.11	P/B	140.09	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	7.80 - 30.00	Perf YTD	49.66%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-48.17%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	99.36%	ATR	2.84
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.43	Volatility	12.82% 13.89%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.32	Prev Close	15.27
Shortable	No	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	765.26K	Price	15.55
Recom	-	SMA20	-8.80%	SMA50	24.13%	SMA200	27.33%	Volume	246,868	Change	1.83%

Jan-28-22 04:05PM	Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-26-22 12:36PM	Why Mainz Biomed Stock Is Crashing Today Motley Fool -28.40%
Jan-25-22 08:00PM	Mainz Biomed Announces Pricing of Follow-on Offering GlobeNewswire -5.81%
Jan-19-22 03:01AM	Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert GlobeNewswire -7.87%
Jan-18-22 07:38AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday InvestorPlace +27.89%
Jan-12-22 07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace +14.41%
03:01AM	Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board GlobeNewswire
Jan-11-22 03:01AM	Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference GlobeNewswire
Jan-05-22 10:12AM	Mainz Biomed Rallies After Gaining Exclusive Rights to mRNA Biomarkers Investing.com +46.39%
09:12AM	Why Mainz Biomed Shares Are Skyrocketing Today? Benzinga
07:30AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace
03:01AM	Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers GlobeNewswire
Dec-21-21 03:01AM	Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process GlobeNewswire
Dec-14-21 03:01AM	Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe GlobeNewswire -6.63%
Dec-07-21 03:01AM	Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic GlobeNewswire
Nov-30-21 03:01AM	Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlerts U.S. Regulatory and Commercial Strategy GlobeNewswire
Nov-18-21 03:01AM	Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board GlobeNewswire
Nov-15-21 06:26AM	20 Stocks Moving in Monday's Pre-Market Session Benzinga +9.90%
03:01AM	Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the Worlds Largest Medical Trade Fair GlobeNewswire
Nov-11-21 03:01AM	Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board GlobeNewswire +9.19%
Nov-08-21 01:45PM	Mainz Biomed Announces Exercise of Over-Allotment Option GlobeNewswire +17.12%
03:42AM	92 Biggest Movers From Friday Benzinga
03:01AM	Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol MYNZ GlobeNewswire
Nov-05-21 05:06PM	Real Good Food and 3 More Companies Went Public Friday. Heres How They Did. Barrons.com
04:23PM	MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market GlobeNewswire
02:57PM	Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher Benzinga
12:35PM	Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet Benzinga
12:24PM	64 Stocks Moving In Friday's Mid-Day Session Benzinga
11:54AM	MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market GlobeNewswire

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience